GlassScriptPhysician profile
Richard Martinoff
NPI 1700823143
$2,498.00
in general payments reported to CMS, 2019-2025
25 companies · $372 in 2025
The $372 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $555 · 2020: $470 · 2021: $470 · 2022: $204 · 2023: $189 · 2024: $239 · 2025: $372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $799.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $317.04 | 2019-2025 | |
| Amarin Pharma, INC. | $311.75 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $246.10 | 2019-2021 | |
| Lilly USA, LLC | $214.08 | 2019-2025 | Zepbound, Mounjaro, Emgality |
| Amgen INC. | $205.22 | 2019-2025 | Evenity, Prolia, Prolia |
| Exact Sciences Corporation | $158.78 | 2024-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $135.65 | 2019-2025 | Veozah |
| Abbvie INC. | $117.70 | 2021 | |
| Novo Nordisk INC | $105.37 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $97.60 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.96 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $64.48 | 2019-2023 | |
| Kowa Pharmaceuticals America, INC. | $60.51 | 2019 | |
| Glaxosmithkline, LLC. | $56.72 | 2023 | Arexvy, Shingrix |
| Alnylam Pharmaceuticals INC. | $54.05 | 2022-2023 | Givlaari |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $49.67 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $44.71 | 2019-2025 | Capvaxive |
| Atricure, INC. | $35.82 | 2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Boston Scientific Corporation | $25.97 | 2025 | Watchman Flx |
| Shield Therapeutics INC | $20.36 | 2024 | |
| Bridgebio Pharma, INC. | $19.88 | 2025 | Attruby |
| Sanofi Pasteur INC. | $17.18 | 2023 | |
| Seqirus USA INC | $15.91 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.98 | 2025 | |
| Ibsa Pharma INC. | $14.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Martinoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.